Skip to main content
Livermore
Livermore
ZHEN

Affinity Asset Advisors, LLC

SEC CIK
0001773195
Latest filing
Aug 13, 2026

Holdings in Q3 2022

Holdings as of Sep 30, 2022, filed Nov 14, 2022. Long positions only; changes compare share counts with Q2 2022.

Institution overview
Positions
47
+7 vs. Q2 2022
Portfolio value
$216.9M
+$34.3M (+18.8%) vs. Q2 2022
Filed
Nov 14, 2022
SEC
Holdings of Affinity Asset Advisors, LLC in Q3 2022
SecurityClassSharesValue% of portfolioShare changeActionHistory
Medicus Sciences AcquisitionG5960S124*W EXP 02/12/20233,333$3.00K<0.1%00.0%Unchanged–
Renovacor, Inc.75989E114*W EXP 99/99/99975,000$6.00K<0.1%00.0%Unchanged–
Vickers Vantage Corp IG9440B115*W EXP 09/15/202100,000$17.0K<0.1%+100,000New–
TNGXTango Therapeutics, Inc.COM81,982$297.0K0.1%+81,982NewHistory
RCORRenovacor, Inc.COM199,490$503.0K0.2%00.0%UnchangedHistory
Immatics N.V.N44445117*W EXP 07/01/202187,204$507.0K0.2%00.0%Unchanged–
VKTXViking Therapeutics, Inc.COM250,000$680.0K0.3%+250,000NewHistory
NAUTNautilus Biotechnology, Inc.COM372,476$790.0K0.4%−94,131−20.2%ReducedHistory
ALPNAlpine Immune Sciences, Inc.COM110,000$792.0K0.4%+110,000NewHistory
CNTACentessa Pharmaceuticals plcSPONSORED ADS242,517$975.0K0.4%+242,517NewHistory
CNTXContext Therapeutics Inc.COM883,654$981.0K0.5%00.0%UnchangedHistory
LIANYLianBioSPONSORED ADS550,000$1.09M0.5%+100,000+22.2%AddedHistory
KALVKalVista Pharmaceuticals, Inc.COM96,318$1.40M0.6%+96,318NewHistory
Intrexon Corp46122TAA0NOTE 3.500% 7/0–$1.46M0.7%–New–
RXDXPrometheus Biosciences, Inc.COM25,000$1.48M0.7%+25,000NewHistory
VINCVincerx Pharma, Inc.COM NEW1,492,771$2.06M0.9%+118,673+8.6%AddedHistory
ACRSAclaris Therapeutics, Inc.COM136,434$2.15M1.0%+36,434+36.4%AddedHistory
GSKGSK plcADR75,000$2.21M1.0%+75,000NewHistory
CLDXCelldex Therapeutics, Inc.COM NEW80,000$2.25M1.0%+40,000+100.0%AddedHistory
COGTCogent Biosciences, Inc.COM154,087$2.30M1.1%+29,087+23.3%AddedHistory
CYTKCytokinetics IncCOM NEW65,000$3.15M1.5%+50,000+333.3%AddedHistory
ARYEARYA Sciences Acquisition Corp VCLASS A ORD SHS352,500$3.46M1.6%00.0%UnchangedHistory
VRNAVerona Pharma plcSPONSORED ADS350,000$3.58M1.6%+350,000NewHistory
ATXSAstria Therapeutics, Inc.COM400,043$3.62M1.7%+400,043NewHistory
ZNTLZentalis Pharmaceuticals, Inc.COM170,000$3.68M1.7%+100,000+142.9%AddedHistory
ACLXArcellx, Inc.COMMON STOCK210,138$3.94M1.8%+135,138+180.2%AddedHistory
MORFMorphic Holding, Inc.COM146,491$4.15M1.9%−69,232−32.1%ReducedHistory
RCKTRocket Pharmaceuticals, Inc.COM267,794$4.27M2.0%+17,328+6.9%AddedHistory
BridgeBio Pharma, Inc.10806XAD4NOTE 2.250% 2/0–$4.44M2.0%–––
BridgeBio Pharma, Inc.10806XAB8NOTE 2.500% 3/1–$4.49M2.1%–––
CBAYCymaBay Therapeutics, Inc.COM1,290,511$4.52M2.1%−81,733−6.0%ReducedHistory
SWTXSpringWorks Therapeutics, Inc.COM175,000$4.99M2.3%+175,000NewHistory
Bellus Health Inc New07987C204COM NEW473,597$5.00M2.3%−19,681−4.0%Reduced–
PNTPOINT Biopharma Global Inc.COM746,576$5.77M2.7%+720,998+2,818.8%AddedHistory
VTYXVentyx Biosciences, Inc.COM170,000$5.93M2.7%+170,000NewHistory
MDGLMadrigal Pharmaceuticals, Inc.COM100,000$6.50M3.0%00.0%UnchangedHistory
AZNAstraZeneca PLCSPONSORED ADR150,000$8.23M3.8%+65,000+76.5%AddedHistory
Nanostring Technologies Inc63009RAD1NOTE 2.625% 5/0–$8.54M3.9%–––
NARIInari Medical, Inc.Stock120,000$8.72M4.0%−102,173−46.0%ReducedHistory
LNTHLantheus Holdings, Inc.Stock130,000$9.14M4.2%−10,000−7.1%ReducedHistory
KURAKura Oncology, Inc.COM675,753$9.23M4.3%−252,503−27.2%ReducedHistory
ASNDAscendis Pharma A/SSPONSORED ADR100,000$10.3M4.8%−25,087−20.1%ReducedHistory
Retrophin Inc761299AB2NOTE 2.500% 9/1–$11.1M5.1%–––
SNYSanofiSPONSORED ADR300,000$11.4M5.3%+300,000NewHistory
GBTGlobal Blood Therapeutics, Inc.COM190,000$12.9M6.0%+190,000NewHistory
KDNYChinook Therapeutics, Inc.COM813,998$16.0M7.4%−123,570−13.2%ReducedHistory
ESTAEstablishment Labs Holdings Inc.COM326,668$17.8M8.2%−33,288−9.2%ReducedHistory

Options (16)

Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.

Option positions of Affinity Asset Advisors, LLC in Q3 2022
SecurityClassPutsCalls
SPYSPDR S&P 500 ETF TrustETF$89.3M–
iShares Russell 2000 ETF464287655ETF$11.5M–
SNYSanofiSPONSORED ADR$9.51M–
AZNAstraZeneca PLCSPONSORED ADR$5.48M–
MDGLMadrigal Pharmaceuticals, Inc.COM$4.87M–
PENPenumbra IncCOM–$4.74M
GSKGSK plcADR$3.24M–
GERNGeron CorpCOM$1.52M$1.47M
LNTHLantheus Holdings, Inc.Stock$2.11M–
FXEInvesco CurrencyShares Euro TrustEURO SHS$1.81M–
VRNAVerona Pharma plcSPONSORED ADS$1.69M–
MISTMilestone Pharmaceuticals Inc.COM–$1.26M
FXBInvesco CurrencyShares British Pound Sterling TrustBRIT POUN STRL$1.07M–
VERVVerve Therapeutics, Inc.COM–$687.0K
ISEEIVERIC bio, Inc.COM–$538.0K
KURAKura Oncology, Inc.COM$507.0K–

Sold out since Q2 2022 (8)

Positions held at the end of Q2 2022 that are gone from this filing.

Positions of Affinity Asset Advisors, LLC sold out since Q2 2022
SecurityClassShares in Q2 2022Value in Q2 2022% of portfolio in Q2 2022History
HZNPHorizon Therapeutics Public Ltd CoSHS75,000$5.98M3.3%History
KRTXKaruna Therapeutics, Inc.COM45,000$5.69M3.1%History
RPTXRepare Therapeutics Inc.COM321,200$4.49M2.5%History
TERNTerns Pharmaceuticals, Inc.COM401,268$995.0K0.5%History
SPRYARS Pharmaceuticals, Inc.COM170,000$721.0K0.4%History
SNCEScience 37 Holdings, Inc.COM279,775$562.0K0.3%History
CRISCuris IncCOM NEW340,349$335.0K0.2%History
VRDNViridian Therapeutics, Inc.COM20,660$239.0K0.1%History